Coya Therapeutics Announces the Completion of a Controlled P

This investigator-initiated, double-blind, placebo-controlled study evaluates the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with...

Related Keywords

United States , Houston , Texas , Americans , Fred Grossman , Jason Thonhoff , Stanley Appel , David Beers , Nasdaq , Centers For Disease , Alzheimer Association , Gates Foundation , Houston Methodist Research Institute , Coya Therapeutics Inc , Coya Therapeutics , Alireza Faridar , Houston Methodist Hospital , Mini Mental State Examination , Disease Control , About Coya Therapeutics , Amyotrophic Lateral Sclerosis , Frontotemporal Dementia ,